Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey | Citedby Results | Digestive Diseases | Karger Publishers

Skip to Main Content

Skip Nav Destination

Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey

Dig Dis (2017) 35 (5): 423–432.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Certolizumab Pegol in Crohn's Disease Management: A Multicentric Brazilian Observational Study

Thaisa Kowalski Furlan
Marcello Imbrizi
Daniela Magro
Paula C. Senger de Castro
Rodrigo Bremer Nones
Eron Fabio Miranda
Paulo G. Kotze

Journal of Coloproctology (2024) 44 (03): e187.

The Essential Role of a Multidisciplinary Approach in Inflammatory Bowel Diseases: Combined Medical-Surgical Treatment in Complex Perianal Fistulas in CD

Jeroen Geldof
Nusrat Iqbal
Janindra Warusavitarne
Ailsa Hart

Clinics in Colon and Rectal Surgery (2022) 35 (01): 021.

Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice

O V Knyazev
A V Kagramanova
A A Lishchinskaya
N G Samsonova
N V Orlova
V A Rogozina
A I Parfenov

Terapevticheskii arkhiv (2018) 90 (6): 74.

Certolizumab pegol

Reactions Weekly (2017) 1672 (1): 64.